SCHEMBL4933929

SCHEMBL4933929

O=C(Nc1ccc(Oc2nccc(Cl)n2)cc1)Nc1ccc(CN2CCN(C(=O)OC(=O)c3ccccc3)CC2)c(C(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 9/20 0.54
CDK2 P24941 2/20 0.54
CDK8 P49336 2/20 0.54
CDK1 P06493 1/20 0.54
SRC P12931 7/20 0.53
KDR P35968 4/20 0.48
MKNK2 Q9HBH9 4/20 0.48
RET P07949 3/20 0.48
FGFR1 P11362 3/20 0.48
BCR P11274 3/20 0.48
MKNK1 Q9BUB5 3/20 0.48
FGFR4 P22455 2/20 0.48
AXL P30530 2/20 0.48
FLT3 P36888 2/20 0.48
MERTK Q12866 2/20 0.48
NTRK1 P04629 2/20 0.48
TEK Q02763 2/20 0.48
NTRK2 Q16620 2/20 0.48
MAP3K7 O43318 2/20 0.48
MAP4K2 Q12851 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4936491 0.87 SRC (0.60) ABL1CDK2CDK8CDK1SRC
SCHEMBL4933269 0.81 KDR (0.75) ABL1CDK2CDK8CDK1SRC
SCHEMBL4937129 0.78 BRAF (0.51) ABL1SRCRETEGFRKIT
SCHEMBL27745523 0.78 BRAF (0.51) ABL1SRCRETMAP3K7MAP4K2
SCHEMBL4938628 0.76 SRC (0.60) ABL1CDK2CDK8CDK1SRC
SCHEMBL4936336 0.75 CDK2 (0.74) ABL1CDK2CDK8CDK1SRC
SCHEMBL4936731 0.72 NR1H2 (0.55) BRAF
SCHEMBL13991087 0.71 KDR (0.70) ABL1CDK2CDK8CDK1SRC
SCHEMBL4936158 0.71 KDR (0.70) ABL1CDK2CDK8CDK1SRC
SCHEMBL3183607 0.71 SRC (0.82) ABL1CDK2CDK8CDK1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312192-A1 Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases BOLD GUIDO 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312192-A1 Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases RET, PRKDC, PRKACA ABL1 51/4885CDK2 83/4885CDK8 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.